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Abstract
Nanoparticles are increasingly used to adjuvant vaccine formulations due to their biocompat-
ibility, ease of manufacture and the opportunity to tailor their size, shape, and physicochemi-
cal properties. The efficacy of similarly-sized silica (Si-OH), poly (D,L-lactic-co-glycolic acid)
(PLGA) and poly caprolactone (PCL) nanoparticles (nps) to adjuvant recombinant cap-
somere presenting antigenic M2emodular peptide from Influenza A virus (CapM2e) was in-
vestigated in vivo. Formulation of CapM2e with Si-OH or PLGA nps significantly boosted the
immunogenicity of modular capsomeres, even though CapM2e was not actively attached to
the nanoparticles prior to injection (i.e., formulation was by simple mixing). In contrast, PCL
nps showed no significant adjuvant effect using this simple-mixing approach. The immune
response induced by CapM2e alone or formulated with nps was antibody-biased with very
high antigen-specific antibody titer and less than 20 cells per million splenocytes secreting in-
terferon gamma. Modification of silica nanoparticle surface properties through amine functio-
nalization and pegylation did not lead to significant changes in immune response. This study
confirms that simple mixing-based formulation can lead to effective adjuvanting of antigenic
protein, though with antibody titer dependent on nanoparticle physicochemical properties.
Introduction
Vaccination has proved to be one of the most influential developments in human health histo-
ry. Over years, vaccination has been based on live attenuated organisms, killed organisms or in-
activated toxins. However, vaccines based on these traditional approaches suffer from
problems including reversion to their virulent state or limited duration of protection [1,2].
These limitations have led to shifting of interest towards recombinant proteins such as subunit
vaccines, based on a specific portion of the pathogen. Subunit vaccines are being preferred over
attenuated live or inactivated whole organism vaccines as they are generally well purified and
characterized, hence have improved safety profile and are easier to scale up over the latter. De-
spite the advantages of subunit vaccines, there are some downsides. For instance, usually anti-
gen by itself is weakly immunogenic, which necessitates use of an adjuvant in formulation [2].
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Selection of a suitable adjuvant is necessary to maintain balance between the upside enhance-
ment of immunogenicity and the downside risk of side effects. In addition to enhancing immu-
nogenicity, adjuvants can be employed to reduce the dosage or number of doses required for
protective immunity.
In recent years, nanoparticles have attracted tremendous interest as a component within ex-
perimental vaccine formulations [3]. The use of nanoparticles in vaccinology is inspired by the
fact that most pathogens have a dimension within the nano-size range [4], and therefore can be
processed efficiently by the immune system, leading to a potent immune response. Nanoparti-
cles are therefore being exploited to elicit desired immune responses for both prophylactic and
therapeutic effects. They are utilized as either delivery systems to enhance antigen processing
or to protect antigen from premature degradation, and/or as an immunostimulant to trigger
immune response [5]. Nanotechnology allows customization of the properties of nanoparticles
such as size, shape and surface charge to meet application requirements, resulting in a great va-
riety of nanoparticles. A variety of biological as well as synthetic nanoparticles have been ap-
proved for human use [6–8], and many more are in clinical or pre-clinical studies [2,9].
Conventionally, the use of nanoparticles as a component in vaccine formulations is predicated
on an assumed requirement for association between the antigen and nanoparticle components,
to gain an adjuvanting effect [10,11]. This association between nanoparticles and antigen usu-
ally involves attachment either by conjugation, adsorption or encapsulation. However, a recent
study has shown that it is possible to achieve an adjuvanting effect by simple mixing of nano-
particles and a sub-unit protein antigen from a virus-like particle, termed a capsomere, that has
viral molecular architecture, which is being used in this study [12].
Virus-like particles (VLPs) are now a well-established vaccine class [6,13,14]. Modularized
VLPs are emerging that allow design for efficacy against diseases different to the parent VLP
through presentation of appropriate antigenic peptide modules within the VLP structure.
VLPs are excellent vaccines as they are self-adjuvanting due to their particle characteristics and
highly immunostimulatory because of their repetitive molecular structures [14,15,16,17]. Re-
cent studies on the VLP-forming protein VP1 from murine polyomavirus (MuPyV) demon-
strate that use of the sub-unit capsomere, the basic building block of a VLP, can lead to high
immunogenic stimulation and protective efficacy with an otherwise immunologically weak
peptide, M2e from influenza [18,19,12]. Studies using capsomeres based on papillomavirus
[20], human respiratory syncytial virus [21] and human mucin-1 cancer antigen [22] also con-
firm that capsomeres are an emerging and interesting vaccine platform, which may retain the
molecular activating signals of viruses but with some advantages including improved stability
[23,24,25], tolerance to antigen incorporation [26] and simplified manufacture [18,27]. How-
ever, as capsomeres do not possess the particle structure of the VLP, formulation with adjuvant
may be necessary, whereas good quality VLPs do not require adjuvant [18]. In this context,
nanoparticles prove an interesting adjuvant class, as their addition to the vaccine formulation
reintroduces the particle component that is inherent in VLPs but lacking in capsomeres, while
the capsomere possesses appropriate and immunostimulatory molecular repetition.
Silica based nanoparticles are widely considered as being biocompatible, are non-toxic and
possess flexible surface chemistry. These features make them attractive candidates for applica-
tion in a vaccine system. Biodegradability is an important feature, which improves the safety
profile of the formulation. PLGA and PCL are two of the most commonly used biodegradable
and biocompatible polymers [2,28]. In particular, PLGA nps owing to their clinical approval
and long safety record, have been widely explored and employed to develop nano-vaccines for
a variety of antigens [29–32]. PCL is more hydrophobic and has a slower degradation profile as
compared to PLGA [33].
Nanoparticle Vaccine Adjuvants
PLOS ONE | DOI:10.1371/journal.pone.0117203 March 10, 2015 2 / 16
of nanoparticles in vaccines, filed by the University of
Queensland. By virtue of their employment they may
receive financial benefit if the University’s
commercialisation company delivers a commercial
return to the University from the patent.
A major goal of the work presented here was to understand, using in vivo tests, the impact
of nanoparticle properties on their efficacy as non-carrier adjuvants for a modular capsomere
sub-unit protein antigen. PEG-coated PLGA and PCL nps were synthesized by emulsion sol-
vent evaporation. Highly monodisperse and spherical nps were prepared. Inorganic silica nps
were obtained commercially. Viral modular capsomeres presenting M2e antigen were synthe-
sized in a microbial expression system [19], and were formulated with the varied nps by simple
mixing. The effects of varying the surface charge of silica nps on their adjuvanting activity, as
well as the impact of selective PEGylation, were also investigated.
Materials and Methods
1.1 Materials
Poly(D,L-lactic-co-glycolic acid) (PLGA, D,L-lactide:glycolide = 65:35, M.W. 40000–75000),
polycaprolactone (PCL, Mn 70000–90000), (3-aminopropyl)triethoxysilane (APTES), o-phe-
nylenediamine dihydrochloride, phosphate citrate buffer and HRP-conjugated goat anti-
mouse IgG1 and IgG2a were purchased from Sigma-Aldrich (St Louis, MI) and used as sup-
plied. 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000](PEGPE) was purchased from Avanti (Alabaster, AL). Polyethylene glycol succinimidyl
ester (mPEG-NSH; MW 5000) was purchased from Nanocs (New York, NY). Biotinylated
M2e peptide was purchased from Peptide 2.0 Inc. (Chantilly, VA). Sodium chloride (NaCl),
potassium chloride (KCl), disodium hydrogen phosphate (Na2HPO4), potassium dihydrogen
phosphate (KH2PO4), Tween 20 and chloroform were obtained from Chem-supply (Gillman,
SA, Australia) and used as supplied.
1.2 Protein expression and purification
Expression vectors for GST-tagged CapM2e (capsomere presenting M2e) and GST-tagged wt
Cap (capsomere without M2e insert) were as described previously [18,19]. Expression vector
was transformed into chemically competent E. coli Rosetta (DE3) pLysS cells (Novagen,
Madison, WI). GST-tagged CapM2e and GST-tagged wt Cap were expressed and purified to
give low-endotoxin (< 2 EU mL-1) CapM2e and wt Cap capsomeres, respectively, as previously
described [19]. Endotoxin removal from GST-tagged CapM2e was performed by phase separa-
tion using Triton X-114 (X114, Sigma-Aldrich, USA) as previously described [19]. Endotoxin
removal from wt Cap was performed by using an anion exchanger, a Vivapure QMini M spin
column (Sartorius Stedim, France) as previously described [18]. Capsomere protein concentra-
tion was adjusted to 0.75 mg mL-1 with endotoxin-free PBS, and endotoxin content tested to be
< 2 EU mL-1. Endotoxin level was analysed using LAL-based assay Endosafe PTS-2005
(Charles River Laboratories, Wilmington, MA). CapM2e and wt Cap capsomeres were ali-
quoted and stored in -80°C until further use.
1.3 Adjuvant Preparation
All adjuvant preparations were conducted in endotoxin free environment.
1.3.1 Synthesis of PLGA and PCL nanoparticles. PLGA and PCL nps were prepared by
an oil-in-water (o/w) emulsion solvent evaporation method as described previously [34]. Brief-
ly, 400 μl of mixture of PLGA or PCL (4 mg) and PEGPE (8 mg) in chloroform was added
dropwise into 4 ml water. Then the solution was sonicated at 10 W (Branson Sonifier 450
microtip probe ultrasonicator, Danbury, CT, USA) for four 25s bursts interspersed with cool-
ing on an ice bath for 60s. The chloroform was separated from the emulsified solution by using
a rotary evaporator (Rotavapor R-215, Büchi, Postfach, Switzerland). Nanoparticles were
Nanoparticle Vaccine Adjuvants
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washed three times by centrifugation (18000 g, 5 mins) using Amicon ultra centrifugal filter de-
vices (Millipore, Billerica, MA, USA) to remove free PEGPE. Endotoxin level in PLGA and
PCL nps were analyzed using LAL-based assay Endosafe PTS-2005 (Charles River Laborato-
ries, Wilmington, MA) and were found to be< 2.5 EU mL-1.
1.3.2 Silica nanoparticle preparation. Commercial silica nps of nominal diameter 50 nm
(Cat. 24040, Polysciences Inc., Warrington, PA) were dialyzed using snake-skin pleated dialysis
membrane (nominal molecular weight cut-off of 10kDa; Thermo Scientific, Rockford, IL,
USA) against PBS at 4°C for 24 h and adjusted to a nominal (based on the product label) silica
concentration of 2 mg mL-1 with PBS. Endotoxin level in silica nps was analyzed using LAL-
based assay Endosafe PTS-2005 (Charles River Laboratories, Wilmington, MA) and was found
to be< 2 EU mL-1.
1.3.3 Silica nanoparticles amine functionalization. Amine-functionalized silica nanopar-
ticles (Si-NH2 nps) was prepared according to literature with some modification [35]. Com-
mercial silica nps as above were dialyzed against Milli Q water at 4°C for 24 h and adjusted to a
nominal silica concentration of 30 mg mL-1 with Milli Q water. Then, nanoparticle solution
was subjected to centrifugal wash (18000 g, 20 mins) with absolute ethanol three times, fol-
lowed by sonication (Branson Ultrasonics Corporation, Danbury, CT) at output 30 for 4 cycles
of 20s to re-suspend in ethanol. Nanoparticle solution in absolute ethanol was incubated with
14% (v/v) (3-aminopropyl)triethoxysilane (APTES; Cat. A3648, Sigma-Aldrich, St Louis, MA)
for 3h with constant stirring. After incubation, nanoparticle-APTES solution was subjected to
centrifugal washing (18000 g, 20 mins) with absolute ethanol three times, followed by sonica-
tion to finally re-suspend in absolute ethanol. Then, amine functionalized nps were dialyzed
against Milli Q water at 4°C for 24h and adjusted to a concentration of 2 mg mL-1 with Milli Q
water. Endotoxin levels in amine-functionalized silica nps was analyzed using a LAL-based
assay Endosafe PTS-2005 (Charles River Laboratories, Wilmington, MA) and was found to be
< 2 EU mL-1.
1.3.4 Silica nanoparticles PEGylation. Pegylated silica nanoparticles (Si-PEG nps) were
prepared by adding polyethylene glycol succinimidyl ester (mPEG-NSH; MW 5000, PDI<1.08,
purity>95%, Cat. PG1-SC-5k, Nanocs Inc) into 3.4 mg mL-1 Si-NH2 nps in 2:1 (mPEG-NSH:
Si-NH2) molar ratio in an endotoxin-free environment. The mixture was stirred at room
temperature for 2 h. Endotoxin level in pegylated silica nps was analyzed using LAL-based
assay Endosafe PTS-2005 (Charles River Laboratories, Wilmington, MA) and was found to
be< 2 EUmL-1.
1.4 Characterization of nanoparticles
1.4.1 Dynamic Light Scattering and Zeta Potential measurement. The hydrodynamic
diameter and surface charge (zeta potential) of nanoparticle solutions were measured with a
Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) using dynamic light scattering
(DLS) and electrophoretic light scattering (ELS), respectively. This instrument employed a 633
nm laser wavelength at a scattering angle of 173° and 4 mWHe-Ne laser power. For dynamic
light scattering (DLS), nanoparticles were diluted 100-fold with water to avoid multiple scatter-
ing effects. Refractive index and viscosity of water were assumed to be 1.33 and 0.89
cP, respectively.
1.4.2 Transmission electron microscopy (TEM) measurement. Two microliters of each
sample (1 mg mL-1) was applied onto 200-mesh carbon-coated grids (Proscitech, Brisbane,
QLD, Australia). Remaining liquid on the grids was blotted with filter paper after 2 min, and
grids were washed with water, stained with 1% (w/v) uranyl acetate for 1 min and then allowed
to air-dry prior to observation with a Jeol 1011 (Jeol Ltd., Tokyo, Japan) microscope at 100 kV
Nanoparticle Vaccine Adjuvants
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accelerating voltage. Electron micrographs were recorded digitally using a side-mounted Mor-
ada camera (Olympus-Soft Imaging System GmbH, Münster, Germany) with iTEM software
(version 3.2, Soft Imaging System GmbH).
1.5 Adsorption studies
50 μg of nanoparticle solution (Si-OH, Si-NH2, Si-PEG, PLGA or PCL nps) in PBS was mixed
with 15 μg of CapM2e solution in PBS at room temperature. All tubes were centrifuged at 22000g,
4°C for 20 min. Supernatant was carefully removed and protein concentration was determined by
high performance liquid chromatography (HPLC) analysis as described previously [36].
1.6 Immunization
Two biological studies were conducted. In the first study, six groups of five female BALB/c
mice (Animal Resources Centre, WA, Australia) were immunized with 15 μg capsomere with-
out M2e inserted (wt Cap) or CapM2e, alone or adjuvanted with 50 μg of Si-OH or PLGA or
PCL nps. M2e peptide adjuvanted with Si-OH nps was used as control group. Adjuvanted
CapM2e was prepared by mixing 15 μg CapM2e with 50 μg of selected adjuvant shortly prior
to injection. Three subcutaneous immunizations were given on days 0, 21 and 42. Blood sam-
ples were taken by tail snip before the first immunization (day 0), followed by eye bleeds on
days 14 and 35. Final blood sample was collected on day 56 by heart puncture. All animal ex-
perimental work was reviewed and approved by The University of Queensland Animal Ethics
Committee (AEC Approval Number: AIBN/058/13/NIRAP/SMART FUTURES). All animals
were cared for humanely in accordance with the Australian Code of Practice for the Care and
Use of Animals for Scientific Purposes.
In the second study, four groups of five female BALB/c mice (Animal Resources Centre,
WA, Australia) were immunized with 3 μg M2e peptide adjuvanted with 50 μg of Si-OH nps or
15 μg CapM2e adjuvanted with 50 μg of Si-OH or Si-NH2 or Si-PEG nps. The immunization
regime was same as that in the first study. All animal experimental work was reviewed and ap-
proved by The University of Queensland Animal Ethics Committee (AEC Approval Number:
AIBN/189/12/NIRAP/SMART FUTURES). All animals were cared for humanely in accor-
dance with the Australian Code of Practice for the Care and Use of Animals for Scientific
Purposes.
1.7 ELISA (Enzyme-linked immunosorbent assay)
Pierce Streptavidin High Binding Capacity (Thermo Fisher Scientific, Waltham, MA) coated
plates were washed 3 times with PBST (137 mMNaCl, 2.7 mM KCl, 10.15 mM Na2HPO4,
1.76 mM KH2PO4, pH 7.4, 0.05% (v/v) Tween 20). Biotinylated M2e peptide (Peptide 2.0 Inc.,
Chantilly, VA) at 10 mg mL-1 in PBS was adsorbed to the plates, 100 μL per well for 2 h at room
temperature. Plates were then washed 3 times with PBST. Plates were incubated with mouse
sera initially at 100-fold dilution followed by four-fold serial dilutions with PBST containing
0.5% (w/v) skim milk (90 min, 37°C). After washing 4 times with PBST, HRP-conjugated goat
anti-mouse IgG1 or IgG2a (Ab97240 or Ab97245, respectively, Abcam, Cambridge, UK) was
added at 20 000- or 10 000-fold dilution, respectively, followed by incubation (90 min, 37°C).
Plates were washed 4 times with PBST and developed (0.4 mg mL-1 o-phenylenediamine dihy-
drochloride (Sigma-Aldrich, St Louis, MA), 50 mM phosphate citrate buffer containing 0.03%
(w/v) sodium perborate) prior to absorbance measurement at 450 nm. End point titers were de-
termined as the highest dilution of serum for which the OD was 3 standard deviations above the
mean optical density of blank wells.
Nanoparticle Vaccine Adjuvants
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1.8 ELISPOT (Enzyme-linked immunospot)
IFN-γ ELISPOT was performed as described previously [37]. Briefly, 14 days after final immu-
nization, splenocytes were restimulated in vitro in the presence or absence of M2e peptide. The
number of spots of cells secreting IFN-γ was counted to assess the frequency of M2e-specific
cytotoxic T-cells. Concanavalin A (Con A) was used as non-specific positive control.
1.9 Statistical Analysis
Statistical analysis was performed using GraphPad Prism Version 5.03 (GraphPad Software
Inc., USA). Comparison of more than two groups was performed with the Tukey’s multiple
comparison tests. Comparison between two groups was performed with t test. p< 0.05 was
considered statistically significant.
Results and Discussion
The adjuvanting efficacy of similarly-sized nanoparticles having different properties was inves-
tigated in in vivo immunogenicity studies, particularly in their roles to adjuvant modular cap-
someres. Modular capsomere presenting antigenic M2e peptide from Influenza A virus
(CapM2e) was synthesized as described previously [18,19,12]. Formulations of CapM2e with
nanoparticles were made by simple mixing prior to injection.
In the first study, adjuvanting efficacy of nanoparticles made of three different materials,
biocompatible inorganic silica (Si-OH), biodegradable poly (lactic-co-glycolic acid) (PLGA)
and polycaprolactone (PCL), were studied. Biocompatible inorganic solid silica nanoparticles
were obtained commercially, whereas PLGA and PCL nanoparticles were prepared using an
oil-in-water (o/w) emulsion solvent evaporation method by employing poly(ethylene glycol)-
distearyl phosphoethanolamine (PEGPE) as the oily emulsifier during the process, as described
[34]. The size of PEG-coated biodegradable nanoparticles could be controlled by varying the
ratio of polymer to the oily emulsifier and also by varying sonication conditions.
Fig. 1 shows the transmission electron micrographs (TEM) of Si-OH, PLGA, and PCL
nanoparticles, revealing the spherical morphology of each type of nanoparticle. The average
size of nanoparticles as observed from TEM is presented in Table 1. TEM images show that
PLGA and PCL nanoparticles were more polydispersed as compared to Si-OH nanoparticles.
Nanoparticle size was also determined using dynamic light scattering (DLS) analysis (Table 1),
which gave a slightly larger size in comparison to TEMmeasurement. TEM gives information
about size and surface morphology (i.e., shape and surface structure of individual nanoparti-
cles) in a dried state while DLS measures the hydrodynamic diameter of particles in solution.
This hydrodynamic diameter is larger than the actual dried diameter as it also takes into ac-
count any associated hydration layer as well as adsorbed organic stabilizers if present. Interpre-
tation is also dependent on solution parameters including viscosity used to estimate the Stokes
diameter in DLS.
Previous studies have shown that 50 nm non-carrier nps can strongly adjuvant the viral
sub-unit capsomere antigen, even in the absence of significant association between nanoparti-
cles and antigen [12]. In the present study, since both CapM2e (isoelectric point pI = 4.9) [38]
and Si-OH nanoparticle (Zeta potential = -41.3 mV) carry net negative charge at physiological
pH, significant interaction between them was not expected and indeed was not found in previ-
ous studies [12]. Significant association between PLGA and PCL nps with CapM2e was also
not expected as each np type includes polyethylene glycol (PEG) chains that will locate to the
np surface and provide for low protein-binding character [39,40]. This expectation was con-
firmed by determining the extent of adsorption of these CapM2e onto these three sets of nano-
particles (Fig. 2).
Nanoparticle Vaccine Adjuvants
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Fig 1. TEM images of nanoparticles A) silica, B) PLGA, C) PCL, D) amine functionalized silica and E)
pegylated silica. Scale bar is 100 nm.
doi:10.1371/journal.pone.0117203.g001
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Fig. 3 shows the endpoint titer of anti-M2e specific total IgG, IgG1, and IgG2a in BALB/c
mice after three subcutaneous immunizations with different formulations. Capsomere without
M2e inserted (wt Cap) was injected as a negative control and, as expected, induced very low
M2e-specific antibodies. A similar result was observed for the negative-control formulation of
M2e peptide with Si-OH nps which also did not induce a specific anti-M2e immune response,
confirming the low immunogenicity of this peptide sub-unit antigen. CapM2e without adju-
vant induced a 104 antibody titer, consistent with results observed earlier [19], revealing a sig-
nificant effect of modularizing the weakly immunogenic peptide M2e into the molecular viral
architecture provided by the capsomere, even in the absence of a particle adjuvant. Fig. 3A
shows that the immunogenicity of CapM2e was boosted significantly, more than ten-fold,
when formulated with Si-OH or PLGA nps. This adjuvanting effect however was not observed
when CapM2e was formulated with PCL nps. PCL has a higher hydrophobicity and slower
degradation profile in comparison to PLGA [41]. A number of studies have demonstrated that
the hydrophobicity of nanoparticles could affect the overall immunogenicity of antigens
[42–44]. Hence, the hydrophobic properties of PCL might affect the interaction of PCL with
the cells of the immune system or with the modular capsomere which could then affect the
Table 1. Characteristics of different nanoparticles.
Nanoparticles Size (dh. nm)±S.D. (DLS) Polydispersity Index (PDI) Size (dt.nm) (TEM)
Silica nanoparticles (Si-OH) 81±2.3 nm 0.076 50 nm
PLGA nanoparticles (Poly(D,L-lactide-co-glycolide) 88±1.8 nm 0.130 40–60 nm
PCL nanoparticles (Poly caprolactone) 87±1.5 nm 0.240 40–70 nm
S.D.- Standard deviation, dh-hydrodynamic diameter
doi:10.1371/journal.pone.0117203.t001
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Fig 3. M2e-specific antibody titers in BALB/c mice following three subcutaneous immunizations with
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mechanisms of antigen processing. It is interesting to observe that two biodegradable nanopar-
ticles with different biodegradation profiles have very different effects on boosting (or not) the
immune response of antigen.
Fig. 3B and C show the anti-M2e specific IgG1 and IgG2a titers of immunized mice that cor-
relate to Th2 (humoral-biased) and Th1 (cellular-biased) responses, respectively. The high IgG1
and low IgG2a titers reveal a Th2- biased immune response to capsomeres with as well as with-
out nanoparticles. This observation is unsurprising as BALB/c mice are known to develop
antibody-predominant immune responses [45]. Further study using Th1-skewed mouse strains,
such as C57BL/6, would be needed to confirm whether Th2-biased immune responses observed
here was due to the mouse strain used in this study, the antigen, or the formulation of CapM2e–
nps. Other published studies related to M2e also resulted in an antibody-predominant immune
response [46,47], while only a few studies have reported cellular response [48,49]. This observa-
tion was further confirmed by ELISPOT assay results (Fig. 4) which show a minimum number
of cells secreting interferon gamma (IFN-γ).
Formulation of CapM2e with Si-OH nps induced the highest antibody titer in comparison to
other formulations. Therefore, further study was conducted on Si-OH np variants, to reveal the
effects of different surface properties on adjuvanting efficacy. Silica nanoparticles, inherently,
have a negatively-charged surface due to the presence of silanol groups. To introduce positive
charges on the surface of Si-OH, (3aminopropyl)triethoxysilane (APTES) was coated on the sur-
face of Si-OH through formation of siloxane bonds by reacting with silanol hydroxyl groups. Si-
NH2 was further modified to shield the surface charge by conjugation of polyethylene glycol
(PEG). This charge transition on the surface of nanoparticles was assessed with zeta potential
measurement, as presented in Table 2. The unmodified Si-OH nps showed an average zeta po-
tential of-41.3 mV, which shifted to +44.5 mV after modification with APTES (Si-NH2). The
zeta potential of Si-NH2 nps was reduced after conjugation with PEG derivative (+3.41 mV)
Fig 4. Determination of IFNγ response in splenocytes.M2e-specific T-cell response was evaluated by
measuring IFNγ secreting cells by enzyme-linked immunospot (ELISPOT). A) Carrier (wt VP1)-specific, B)
M2e-specific, C) positive control (Concanavalin A (Con A)). No significant difference was observed between
the mean value of each group (p>0.05).
doi:10.1371/journal.pone.0117203.g004
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which indicates overall surface coverage of nanoparticles by PEG chains. There was an increase
in the size of nps after each modification step (Table 2).
Fig. 5 shows the endpoint titer of anti-M2e specific IgG1 in mice after three subcutaneous
immunizations with different formulations. No significant differences in immune response be-
tween different nanoparticle formulations with negative, positive and neutral surface charges
could be observed statistically as these different groups were compared by one-way ANOVA
followed by Tukey’s multiple comparison. Studies have reported that nanoparticle physico-
chemical properties including size [10,50], shape [51,52], surface charge [53,54] and hydropho-
bicity [43] influence the interaction of nanoparticles with the immune system [42]. Several in
vivo studies have reported that surface charge of nanoparticles affects the immune response of
formulations [55,56]. However, Foged and co-workers reported no effect of surface charge of
nanoparticles of similar sizes on their uptake by dendritic cells (DCs) [53]. In this present
study, the immune response might already be at its maximum and thus no further boosting of
immunogenicity of formulation could be observed on changing the surface charge of
Table 2. Characteristics of silica nanoparticles with different surface properties.
Nanoparticles Size (dh.nm)±S.D. (DLS) Polydispersity Index (PDI) Zeta Potential (mV)
Silica nanoparticles (Si-OH) 81±2.3 nm 0.076 -41±2.1 mV
Silica nanoparticles with amine functionalization (Si-NH2) 103±2.7 nm 0.049 +45±1.4 mV
PEG-coated silica nanoparticles with amine functionalization (Si-PEG) 129±1.9 nm 0.130 +3.4±0.5 mV
S.D.- Standard deviation, dh-hydrodynamic diameter
doi:10.1371/journal.pone.0117203.t002
Fig 5. M2e-specific IgG1 titer in BALB/c mice following three subcutaneous immunizations with
different formulations. *, p<0.05; **, p<0.01; ***, p<0.001; ns = not significant.
doi:10.1371/journal.pone.0117203.g005
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nanoparticles. Further study is needed to fully explore and mechanistically understand these ef-
fects, for different antigen classes, and represents ongoing work in our laboratory.
This study explored the potential of various nanoparticles as a non-carrier adjuvant to mod-
ular capsomere, in contrast to a conventional attachment approach which involves loading of
antigen either on the particle surface by chemical conjugation or physical adsorption or within
the particle by encapsulation or entrapment. This non-attachment approach is increasingly
being investigated [12,57], particularly as it offers much simpler formulation by mixing.
Wibowo et.al [12] showed that non-carrier silica nanoparticles significantly boosted the immu-
nogenicity of a subunit antigen even in the absence of significant association between these two
components. However, a study by Zhang et al. [57] did not show enhanced IgG response by
simple mixing. This difference is perhaps due to the absence of PAMPs in the OVA antigen
that they used in comparison to viral capsomere used in the study by Wibowo et al. [12]. The
presence of PAMPs in viral capsomere can act as danger signals that activate pattern recogni-
tion receptors on cells of the immune system [58]. Also, the difference in immunogenicity
might be due to particle size (500 nm in Zhang et al. study, 50 nm inWibowo et al.). Wibowo
et al. clearly showed the striking effect of silica particle size on the adjuvanting efficacy, where
boosting of immune response was observed for 50 nm sized silica nanoparticles but not for the
larger (1000 nm) counterpart. Other studies have shown that size of particles is critical for their
adjuvanting activity [10,59,60]. Nevertheless, Zhang et al. demonstrated that the addition of
non-attached formulation to a nanoparticle-encapsulated antigen formulation enhanced anti-
gen-specific IgG level and avidity, as well as increased cytokine secretion and memory T cell
generation [57], highlighting the potential of nanoparticles as a non-carrier adjuvant class.
In this study, the various nanoparticles used have similar size but different physicochemical
characteristics. The results demonstrated the superiority of silica nanoparticle in comparison
to PLGA and PCL, possibly due to the ability of silica nanoparticles to induce several immu-
nostimulatory cytokines, such as IFN0γ, IL-4 and IL-3 [61], or possibly because PLGA and
PCL nanoparticles were not at their optimal size. Yan et al. [60] reported size-dependent adju-
vanting effects for different particle types, and found that there exists an optimum size range
for maximum adjuvanting efficacy for each type of particle.
This study further demonstrates the potential of the modular capsomere as a vaccine plat-
form, as shown in previous studies [12,18,19]. A significant effect of modularizing the weakly
immunogenic M2e antigen into the molecular viral architecture of a capsomere on immunoge-
nicity was observed, suggesting that even in the absence of particle stimulation, capsomeres
still retain the molecular activating signals of viruses. Moreover, nanoparticles can further en-
hance capsomere immunogenicity by introducing the particle component which is lacking in
the capsomere structure. The low amount of endotoxin presence in the formulation suggests
that the immunogenicity observed was not due to the bacterial signals. This two-component
formulation prepared by simple mixing can potentially activate the immune system through
two different pathways, leading to the observed strong immune response. This simple mixing
approach, by eliminating the complexity of antigen conjugation or incorporation, may simplify
approaches for the preparation of safe and efficacious nanoparticle-containing vaccines,
though in a fashion that is nanoparticle and probably antigen specific.
Conclusion
This study investigated the effects of composition and surface properties of non-carrier nano-
particles on their adjuvanting efficacy for modular capsomeres presenting influenza M2e anti-
gen (CapM2e). Our findings showed that Si-OH and PLGA nps could boost the
immunogenicity of these capsomeres, with the immune response being predominantly
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antibody biased and close to the maximum expected. It was observed that there was no signifi-
cant difference on adjuvanting effect of Si-OH nps after varying their surface properties. Induc-
tion of maximal immune response by these nanoparticle adjuvanted modular capsomere
formulations is attributed to combined synergistic effects of viral molecular and particle signals
contributed by the capsomere protein and nanoparticle components, respectively. This simple
mixed formulation of subunit antigen (capsomere) augmented with nanoparticles can prove to
be a more robust formulation than for simpler antigens where in the absence of viral molecular
signal, the properties of the adjuvant particle may become more critical. Understanding the
mechanism of action of these formulations through further studies will be important for accel-
erating the rational design of nanoparticle-containing vaccines.
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